Analyzing Apricus Biosciences (APRI) & Its Peers
Apricus Biosciences (NASDAQ: APRI) is one of 113 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Apricus Biosciences to similar businesses based on the strength of its profitability, risk, valuation, earnings, institutional ownership, dividends and analyst recommendations.
Volatility & Risk
Apricus Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Apricus Biosciences’ peers have a beta of 0.87, indicating that their average share price is 13% less volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Apricus Biosciences and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Apricus Biosciences Competitors||951||3817||6057||164||2.49|
Apricus Biosciences presently has a consensus target price of $4.50, suggesting a potential upside of 151.40%. As a group, “Pharmaceuticals” companies have a potential upside of 22.56%. Given Apricus Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Apricus Biosciences is more favorable than its peers.
Institutional and Insider Ownership
15.3% of Apricus Biosciences shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.6% of Apricus Biosciences shares are held by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Apricus Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Apricus Biosciences||$5.76 million||-$10.05 million||2.63|
|Apricus Biosciences Competitors||$7.79 billion||$2.46 billion||0.03|
Apricus Biosciences’ peers have higher revenue and earnings than Apricus Biosciences. Apricus Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Apricus Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Apricus Biosciences Competitors||-3,194.35%||-54.66%||-8.67%|
Apricus Biosciences peers beat Apricus Biosciences on 7 of the 12 factors compared.
About Apricus Biosciences
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Receive News & Stock Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related stocks with our FREE daily email newsletter.